ArriVent BioPharma Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

AVBP$14.16+3.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets


· · September 30, · · December 31, ·
· 2024 · 2023
Assets · ·
Current assets: · ·
Cash and cash equivalents	$282,855	$150,389
Prepaid expenses and other current assets	9,543	9,579
Total current assets	292,398	159,968
Right of use assets – operating leases	187	291
Deferred offering costs	—	2,732
Other assets	126	107
Total assets	$292,711	$163,098

Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable	$4,646	$4,532
Accrued expenses	10,359	6,952
Operating lease liabilities	157	140
Total current liabilities	15,162	11,624
Operating lease liabilities, net of current amount	56	177
Total liabilities	15,218	11,801

Commitments and contingencies (Note 7)

Series A convertible preferred stock $0.0001 par value, 150,000,000 shares authorized; 150,000,000 shares issued and outstanding at December 31, 2023	—	149,865
Series B convertible preferred stock $0.0001 par value, 147,619,034 shares authorized; 147,619,034 shares issued and outstanding at December 31, 2023	—	154,625

Stockholders’ equity (deficit):
Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding	—	—
Common stock $0.0001 par value, 200,000,000 shares authorized; 33,694,355 and 2,745,480 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	3	—
Additional paid-in capital	495,190	4,652
Accumulated deficit	(217,700)	(157,845)
Total stockholders’ equity (deficit)	277,493	(153,193)
Total liabilities, convertible preferred stock and stockholders’ equity	$292,711	$163,098

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.